The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 02, 2021

Filed:

Apr. 02, 2018
Applicant:

Sanofi, Paris, FR;

Inventors:

Jana Albrecht, Frankfurt, DE;

Cédric Barriere, Paris, FR;

Christian Beil, Frankfurt, DE;

Jochen Beninga, Eltville, DE;

Chantal Carrez, Thiais, FR;

Stéphane Guerif, Paris, FR;

Katja Kroll, Frankfurt, DE;

Christian Lange, Holler, DE;

Cendrine Lemoine, Massy, FR;

Wulf-Dirk Leuschner, Niedernhausen, DE;

Ercole Rao, Moerfelden-Walldorf, DE;

Marion Schneider, Hofheim, DE;

Marie-Cécile Wetzel, Paris, FR;

Peter Wonerow, Frankfurt, DE;

Assignee:

SANOFI, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); C07K 2318/00 (2013.01); G01N 2333/7155 (2013.01);
Abstract

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.


Find Patent Forward Citations

Loading…